Seminars in nephrology最新文献_第4页

Adoptive Immune Effector Cell Therapies in Cancer and Solid Organ Transplantation: A Review 癌症和实体器官移植中的适应性免疫效应细胞疗法：综述。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-01-01 DOI: 10.1016/j.semnephrol.2024.151498

Brittany Schreiber MD , Sudipta Tripathi PhD , Sarah Nikiforow MD, PhD , Anil Chandraker MBChB

{"title":"Adoptive Immune Effector Cell Therapies in Cancer and Solid Organ Transplantation: A Review","authors":"Brittany Schreiber MD , Sudipta Tripathi PhD , Sarah Nikiforow MD, PhD , Anil Chandraker MBChB","doi":"10.1016/j.semnephrol.2024.151498","DOIUrl":"10.1016/j.semnephrol.2024.151498","url":null,"abstract":"<div>Cancer is one of the most devastating complications of kidney transplantation and constitutes one of the leading causes of morbidity and mortality among solid organ transplantation (SOT) recipients. Immunosuppression, although effective in preventing allograft rejection, inherently inhibits immune surveillance against oncogenic viral infections and malignancy. Adoptive cell therapy, particularly immune effector cell therapy, has long been a modality of interest in both cancer and transplantation, though has only recently stepped into the spotlight with the development of virus-specific T-cell therapy and chimeric antigen receptor T-cell therapy. Although these modalities are best described in hematopoietic cell transplantation and hematologic malignancies, their potential application in the SOT setting may hold tremendous promise for those with limited therapeutic options. In this review, we provide a brief overview of the development of adoptive cell therapies with a focus on virus-specific T-cell therapy and chimeric antigen receptor T-cell therapy. We also describe the current experience of these therapies in the SOT setting as well as the challenges in their application and future directions in their development.</div>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":"44 1","pages":"Article 151498"},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140330108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pediatric Kidney Transplantation: Cancer and Cancer Risk 小儿肾移植：癌症与癌症风险

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-01-01 DOI: 10.1016/j.semnephrol.2024.151501

Kaitlyn E. Order MD, Nancy M. Rodig MD

引用次数: 0

Infections and Acute Kidney Injury: A Global Perspective 感染与急性肾损伤：全球视角

IF 3.3 3区医学

Seminars in nephrology Pub Date : 2023-12-28 DOI: 10.1016/j.semnephrol.2023.151466

Anthony Batte, Lubaba Shahrin, Rolando Claure-Del Granado, Valerie A. Luyckx, Andrea L. Conroy

{"title":"Infections and Acute Kidney Injury: A Global Perspective","authors":"Anthony Batte, Lubaba Shahrin, Rolando Claure-Del Granado, Valerie A. Luyckx, Andrea L. Conroy","doi":"10.1016/j.semnephrol.2023.151466","DOIUrl":"https://doi.org/10.1016/j.semnephrol.2023.151466","url":null,"abstract":"Globally, there are an estimated 13.3 million cases of acute kidney injury (AKI) annually. Although infections are a common cause of AKI globally, most infection-associated AKI occurs in low- and lower-middle-income countries. There are marked differences in the etiology of infection-associated AKI across age groups, populations at risk, and geographic location. This article provides a global overview of different infections that are associated commonly with AKI, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human immunodeficiency virus, malaria, dengue, leptospirosis, tick-borne illnesses, and viral hemorrhagic fevers. Further discussion focuses on infectious conditions associated with AKI including sepsis, diarrheal diseases and pregnancy, peripartum and neonatal AKI. This article also discusses the future of infection-associated AKI in the framework of climate change. It explores how increased investment in achieving the sustainable development goals may contribute to the International Society of Nephrology's 0 by 25 objective to curtail avoidable AKI-related fatalities by 2025.","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":"7 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139068524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Introduction: ISN Frontiers Meeting on “Infections and the Kidney” 导言：关于 "感染与肾脏 "的 ISN 前沿会议

IF 3.3 3区医学

Seminars in nephrology Pub Date : 2023-12-18 DOI: 10.1016/j.semnephrol.2023.151464

Saraladevi Naicker, Chih-Wei Yang, Vivekanand Jha

引用次数: 0

Avoiding Systemic Heparinization During Hemodialysis: How the Dialysis Setup Might Help. 在血液透析过程中避免全身肝素化：透析装置如何提供帮助？

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2023-11-01 Epub Date: 2024-01-13 DOI: 10.1016/j.semnephrol.2023.151483

Florine V Janssens, Björn Meijers, Karlien François

{"title":"Avoiding Systemic Heparinization During Hemodialysis: How the Dialysis Setup Might Help.","authors":"Florine V Janssens, Björn Meijers, Karlien François","doi":"10.1016/j.semnephrol.2023.151483","DOIUrl":"10.1016/j.semnephrol.2023.151483","url":null,"abstract":"Heparin is the most widely used anticoagulant for maintaining patency of the extracorporeal blood circuit during intermittent hemodialysis. Inadvertently, this leads to systemic heparinization of the patient. Repeated intermittent heparinization during hemodialysis has been associated with increased bleeding risks and metabolic and immunologic effects. Alternative strategies for minimizing systemic anticoagulation encompass dilution methods, regional citrate anticoagulation, priming of the extracorporeal circuit, and modifications to dialyzer membranes and dialysate composition. The effectiveness of these alternatives in maintaining patency of the extracorporeal circuit varies substantially. Although most studies have focused on particular changes in the hemodialysis setup, several combined interventions for adapting the hemodialysis setup are now being studied. This narrative review aims to present an overview of the current landscape of hemodialysis setup strategies aimed at limiting or avoiding systemic anticoagulation during treatment. Additionally, this review intends to shed light on the underlying pathophysiological mechanisms that contribute to variations observed in reported outcomes.","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":" ","pages":"151483"},"PeriodicalIF":2.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lipid and Bone Effects of Heparin Use During Hemodialysis. 血液透析期间使用肝素对血脂和骨骼的影响

IF 3.3 3区医学

Seminars in nephrology Pub Date : 2023-11-01 Epub Date: 2024-01-09 DOI: 10.1016/j.semnephrol.2023.151480

Bernd Stegmayr, Li Zuo, Ward Zadora

引用次数: 0

Clotting Propensity of Surface-Treated Membranes in a Hemodialysis Set-up That Avoids Systemic Anticoagulation. 避免全身抗凝的血液透析装置中表面处理膜的凝血倾向

IF 3.3 3区医学

Seminars in nephrology Pub Date : 2023-11-01 Epub Date: 2024-01-23 DOI: 10.1016/j.semnephrol.2023.151482

Hideki Kawanishi, Masahide Koremoto, Casper F M Franssen, Marco van Londen

引用次数: 0

Anticoagulation for Hemodialysis: A Hidden Quest to Ensure Safe Dialysis. 血液透析中的抗凝治疗：确保安全透析的隐性探索。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2023-11-01 Epub Date: 2024-01-10 DOI: 10.1016/j.semnephrol.2023.151485

Karlien François, Björn Meijers

引用次数: 0

Patient Perspectives on Clotting in the Extracorporeal Circuit and Decision-Making Regarding Anticoagulation Therapy. 患者对体外循环凝血的看法以及抗凝疗法的决策。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2023-11-01 Epub Date: 2024-01-17 DOI: 10.1016/j.semnephrol.2023.151475

Chandana Guha, Daniel Gallego, Amanda Grandinetti, Madeleine Warren, Allison Jaure

{"title":"Patient Perspectives on Clotting in the Extracorporeal Circuit and Decision-Making Regarding Anticoagulation Therapy.","authors":"Chandana Guha, Daniel Gallego, Amanda Grandinetti, Madeleine Warren, Allison Jaure","doi":"10.1016/j.semnephrol.2023.151475","DOIUrl":"10.1016/j.semnephrol.2023.151475","url":null,"abstract":"Clotting of the extracorporeal circuit is a complication in the process of hemodialysis that can result in missed or shortened dialysis sessions, higher nursing workload, and elevated cost of treatment. Repercussions of inadequate dialysis may include patient blood loss, fluid overload, build-up of minerals, higher hospitalization rates, and poor quality of life, contributing to increased patient distress. Preventing clotting through anticoagulation therapy is the key to maintaining patency of the dialysis circuit and supporting dialysis adequacy. Despite the severe consequences of clotting in the extracorporeal circuit patients encounter, their perspectives on decision-making regarding anticoagulation therapy are not well known. In this article, we discuss patients' perspectives and priorities around clotting and anticoagulation therapy and outline ways to support their treatment through shared decision-making. Insights into patients' perspectives on addressing thrombotic complications of the extracorporeal circuit can inform strategies to improve care and outcomes for patients receiving hemodialysis.","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":" ","pages":"151475"},"PeriodicalIF":2.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139486355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factor XI Inhibitors: Potential Role in End-Stage Kidney Disease. 因子 XI 抑制剂：在终末期肾病中的潜在作用。

IF 3.3 3区医学

Seminars in nephrology Pub Date : 2023-11-01 Epub Date: 2024-01-24 DOI: 10.1016/j.semnephrol.2023.151484

Matthew Ades, Camille Simard, Thomas Vanassche, Peter Verhamme, John Eikelboom, Thomas A Mavrakanas

{"title":"Factor XI Inhibitors: Potential Role in End-Stage Kidney Disease.","authors":"Matthew Ades, Camille Simard, Thomas Vanassche, Peter Verhamme, John Eikelboom, Thomas A Mavrakanas","doi":"10.1016/j.semnephrol.2023.151484","DOIUrl":"10.1016/j.semnephrol.2023.151484","url":null,"abstract":"Patients with end-stage kidney disease (ESKD) experience a high thrombotic risk but are also at increased risk of bleeding. There is an unmet need for safer antithrombotic therapy in patients with ESKD on hemodialysis. Factor XI (FXI) represents an attractive therapeutic target for anticoagulation because of the potential to mitigate the bleeding risks associated with currently approved anticoagulants, especially in patients at high risk of bleeding. FXI inhibition is also an attractive option in settings where coagulation is activated by exposure of the blood to artificial surfaces, including the extracorporeal circuit during hemodialysis. Therapies targeting FXI that are in the most advanced stages of clinical development include antisense oligonucleotides, monoclonal antibodies, and synthetic small molecules, which serve either to lower FXI levels or block its physiological effects. This review article presents the most recent pharmacological data with FXI inhibitors, briefly describes phase 2 and 3 clinical trials with these agents, and critically examines the potential future use of FXI inhibitors for extracorporeal circuit anticoagulation in patients with ESKD. In addition, laboratory monitoring and reversal of FXI inhibitors are briefly discussed.","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":" ","pages":"151484"},"PeriodicalIF":3.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139565007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0